|1.||Coppola, Giangennaro: 8 articles (07/2015 - 11/2010)|
|2.||Verrotti, Alberto: 7 articles (07/2015 - 11/2010)|
|3.||Kluger, Gerhard: 7 articles (11/2014 - 02/2007)|
|4.||Curatolo, Paolo: 6 articles (11/2014 - 11/2010)|
|5.||Kluger, G: 6 articles (09/2012 - 05/2008)|
|6.||Narurkar, Milind: 5 articles (05/2011 - 12/2009)|
|7.||Parisi, Pasquale: 4 articles (09/2014 - 11/2010)|
|8.||Mann, Allison: 4 articles (02/2011 - 08/2009)|
|9.||Moavero, Romina: 3 articles (11/2014 - 11/2012)|
|10.||Cusmai, Raffaella: 3 articles (11/2014 - 11/2012)|
01/01/2006 - "Relative to placebo, adjunctive rufinamide significantly reduced the frequency of partial seizures per 28 days in adult patients with inadequately controlled partial seizures in two well designed trials of approximate, equals3 months duration, with a higher proportion of rufinamide recipients achieving a reduction of >or=50% in partial seizure frequency per 28 days. "
11/01/2012 - "In a randomized controlled trial in the LGS population, adjunctive rufinamide therapy has been shown to offer significantly greater reduction in total seizure frequency and tonic-atonic seizure frequency in comparison to placebo. "
03/01/2012 - "A significantly higher proportion of rufinamide than placebo recipients recorded an improvement in seizure severity at the end of treatment. "
04/01/2009 - "On this background, a new and structurally novel seizure medication, rufinamide, has been found to be beneficial in the treatment of seizures in this syndrome. "
01/01/2006 - "Rufinamide recipients experienced significantly greater reductions from baseline than placebo recipients in the median frequency of total seizures and tonic-atonic seizures per 28 days and demonstrated improvements in seizure severity. "
11/01/2012 - "The aim of this prospective study was to evaluate the safety and efficacy of add-on Rufinamide in the treatment of childhood focal drug resistant epilepsy. "
05/01/2011 - "Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis."
07/01/2015 - "Rufinamide seems to be efficacious and safe in patients with epileptic encephalopathies associated with pharmacoresistant epilepsy; further and larger clinical reports and controlled studies could confirm the usefulness of this anticonvulsant drug. "
12/01/2014 - "Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials."
08/01/2014 - "Reports of studies evaluating rufinamide as an add-on therapy in children and adolescents with refractory epilepsy are restricted to a few publications. "
02/01/2011 - "Rufinamide was most effective in patients with drop-attacks and (bi)frontal spike-wave discharges."
01/01/2010 - "If society is prepared to pay at least 250 pounds for a 1% increase in the number of successfully treated LGS patients, in terms of a 50% reduction in the frequency of drop attacks, the probability of the treatment with rufinamide being cost effective is >80%. "
01/01/2010 - "Rufinamide appears to be especially effective for atonic or drop attack seizures. "
02/01/2007 - "In a randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop attacks (median change -42.5% vs +1.4% with placebo) and total seizures (-32.1% vs -11.7% with placebo), accompanied by significantly higher responder rates. "
03/01/2012 - "The cost-effectiveness analysis suggested that rufinamide would be associated with incremental costs of £62 (drop attacks) or £2151 (total seizures) per 1% increase in the number of patients achieving a >50% reduction in seizure frequency over 3 years. "
|4.||Partial Epilepsies (Epilepsy, Partial)
01/01/2013 - "The present study aimed to assess the efficacy and tolerability of rufinamide as adjunctive drug for the treatment of a large series of children, adolescents and adults with refractory cryptogenic or symptomatic focal epilepsy. "
03/01/2011 - "Treatment of malignant migrating partial epilepsy of infancy with rufinamide: report of five cases."
02/01/2011 - "Refractory focal epilepsy in a patient with methylmalonic aciduria: case report on positive and long-lasting effect of rufinamide."
03/01/2009 - "The results of our study suggest that the efficacy of rufinamide in patients with generalized epilepsy might be comparable to that in patients with LGS, whereas rufinamide was less effective in patients with partial epilepsy."
08/01/2007 - "Rufinamide has shown promise as adjunctive treatment for Lennox-Gastaut syndrome and may have some role in localization related epilepsies as well."
02/01/2011 - "The purpose of this study was to determine the safety and efficacy of rufinamide for treatment of epileptic spasms. "
02/01/2011 - "Of all 107 children treated with rufinamide during the study period, 38 (36%) had epileptic spasms. "
02/01/2011 - "Rufinamide appears to be a well-tolerated and efficacious adjunctive therapeutic option for children with epileptic spasms. "
02/01/2011 - "We retrospectively reviewed patients treated with rufinamide for epileptic spasms from January 2009 to March 2010. "
02/01/2011 - "Rufinamide for the treatment of epileptic spasms."
|1.||Lennox-Gastaut type Epileptic encephalopathy
|5.||clobazam (HR 376)
|6.||Anticonvulsants (Antiepileptic Drugs)
|2.||Electric Stimulation Therapy (Electrotherapy)